GGrantIndex
← Leaderboards

Alan Pestronk

Washington University

$192,545
Attributed
$192,545
Total exposure
22
Grants
13
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $70.3K · FY200507
$100K$75K$50K$25K$0
'05
'06
'07

Funding mix

By agency

NIH$192,545 · 22

By mechanism

M01$192,545 · 22

Top collaborators

No co-investigators on record.

Most similar at Washington University

Same institution · by research overlap

Others in their field

Top investigators on “Human Subject

Research focus

Human SubjectHuman Therapy EvaluationClinical ResearchDrug Screening /EvaluationAmyotrophic Lateral SclerosisNervous System Disorder ChemotherapyNeuromuscular Disorder ChemotherapyMuscle StrengthClinical TrialsResourcesPlacebosResearch PersonnelInstitutionFundingMaleComputer Retrieval Of Information On Scientific Projects DatabaseGrantSourceUnited States National Institutes Of HealthNeuroprotectantsMuscle Disorder ChemotherapyMuscular DystrophyChild (0-11)Adolescence (12-20)

Grant awards (40)

COMBINATION TRIAL IN ALS$3,932
M01 · FY2007 · RR · contact PI
TRANSLATIONAL RESEARCH IN THE DYSTROPHINOPATHIES$2,575
M01 · FY2007 · RR · contact PI
MINOCYCLINE STUDY IN ALS PATIENTS$1,084
M01 · FY2007 · RR · contact PI
CLINICAL TRIAL OF CEFTRIAXONE IN SUBJECTS WITH ALS$949
M01 · FY2007 · RR · contact PI
PENTOXIFYLLINE AS A RESCUE TREATMENT IN DUCHENNE MUSCULAR DYSTROPHY$542
M01 · FY2007 · RR · contact PI
HIGH DOSE COQ10 IN ALS$406
M01 · FY2007 · RR · contact PI
STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY (DMD)$271
M01 · FY2007 · RR · contact PI
MINOCYCLINE STUDY IN ALS PATIENTS$23,740
M01 · FY2006 · RR · contact PI
TRANSLATIONAL RESEARCH IN THE DYSTROPHINOPATHIES$12,078
M01 · FY2006 · RR · contact PI
PENTOXIFYLLINE AS A RESCUE TREATMENT IN DUCHENNE MUSCULAR DYSTROPHY$4,582
M01 · FY2006 · RR · contact PI
STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY (DMD)$2,499
M01 · FY2006 · RR · contact PI
PILOT TRIAL OF PENTOXIFYLLINE IN DUCHENNE MUSCULAR DYSTROPHY (DMD)$2,499
M01 · FY2006 · RR · contact PI
HIGH DOSE COQ10 IN ALS$1,666
M01 · FY2006 · RR · contact PI
MINOCYCLINE STUDY IN ALS PATIENTS$41,488
M01 · FY2005 · RR
TRANSLATIONAL RESEARCH IN THE DYSTROPHINOPATHIES$11,913
M01 · FY2005 · RR
CLINICAL TRIAL OF CELEBREX IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS$6,984
M01 · FY2005 · RR
USE OF COQ10 IN ALS PATIENTS$5,751
M01 · FY2005 · RR
PILOT TRIAL OF PENTOXIFYLLINE IN DUCHENNE MUSCULAR DYSTROPHY (DMD)$3,287
M01 · FY2005 · RR
TRANSLATIONAL RESEARCH IN THE DYSTROPHINOPATHIES$829
M01 · FY2005 · RR
Clinical Trial of Celebrex in Subjects with Amyotrophic Lateral Sclerosis.$36,408
M01 · FY2004 · RR
Use of CoQ10 in ALS Patients$21,397
M01 · FY2004 · RR
Minocycline Study in ALS Patients$7,665
M01 · FY2004 · RR
Efficacy and safety of oxandrolone for boys with Duchenne's muscular dystrophy$0
M01 · FY2002 · RR
SR 57746A IN PATIENTS WITH ALS RECEIVING RILUZOLE$0
M01 · FY2002 · RR
RECOMBINANT HUMAN NERVE GROWTH FACTOR IN PATIENTS WITH DIABETIC NEUROPATHY$0
M01 · FY2002 · RR
RANDOMIZED CLINICAL TRIAL OF OXANDRIN ON STRENGTH IN BOYS WITH DMD$0
M01 · FY2002 · RR
STUDY OF SR 57764A IN PATIENTS WITH ALS$0
M01 · FY2002 · RR
RITUXAN IN POLYNEUROPATHIES ASSOCIATED WITH SERUM IGM AUTOANTIBODIES$0
M01 · FY2002 · RR
STUDY OF SR 57764A IN PATIENTS WITH ALS$0
M01 · FY2001 · RR
Efficacy and safety of oxandrolone for boys with Duchenne's muscular dystrophy$0
M01 · FY2001 · RR
RITUXAN IN POLYNEUROPATHIES ASSOCIATED WITH SERUM IGM AUTOANTIBODIES$0
M01 · FY2001 · RR
RECOMBINANT HUMAN NERVE GROWTH FACTOR IN PATIENTS WITH DIABETIC NEUROPATHY$0
M01 · FY2001 · RR
RANDOMIZED CLINICAL TRIAL OF OXANDRIN ON STRENGTH IN BOYS WITH DMD$0
M01 · FY2001 · RR
SR 57746A IN PATIENTS WITH ALS RECEIVING RILUZOLE$0
M01 · FY2001 · RR
STUDY OF SR 57764A IN PATIENTS WITH ALS$0
M01 · FY2000 · RR
Efficacy and safety of oxandrolone for boys with Duchenne's muscular dystrophy$0
M01 · FY2000 · RR
RITUXAN IN POLYNEUROPATHIES ASSOCIATED WITH SERUM IGM AUTOANTIBODIES$0
M01 · FY2000 · RR
RECOMBINANT HUMAN NERVE GROWTH FACTOR IN PATIENTS WITH DIABETIC NEUROPATHY$0
M01 · FY2000 · RR
RANDOMIZED CLINICAL TRIAL OF OXANDRIN ON STRENGTH IN BOYS WITH DMD$0
M01 · FY2000 · RR
SR 57746A IN PATIENTS WITH ALS RECEIVING RILUZOLE$0
M01 · FY2000 · RR